Celularity (CELU) Other Non-Current Liabilities (2019 - 2025)
Celularity (CELU) posted quarterly Other Non-Current Liabilities of $92000.0 for Q4 2025, down 67.14% year-over-year from $280000.0 in Q4 2024, and down 65.8% quarter-over-quarter from $269000.0 in Q3 2025.
Celularity (CELU) Other Non-Current Liabilities (2019 - 2025) Analysis & Trends
Celularity (CELU) has reported Other Non-Current Liabilities for 7 consecutive years, with $92000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Liabilities fell 67.14% year-over-year to $92000.0; the TTM figure through Dec 2025 stood at $92000.0 (down 67.14% YoY), while the FY2025 annual figure was $92000.0, down 67.14% from the prior year.
- Other Non-Current Liabilities retreated to $92000.0 in Q4 2025 per CELU's latest filing, from $269000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $37.2 million in Q3 2021 and bottomed at $92000.0 in Q4 2025.
- Historically, Other Non-Current Liabilities has averaged $8.0 million across 5 years, with a median of $3.2 million in 2022.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities tumbled 97.9% — and 2024, when it soared 4645.91%.
- Celularity's Other Non-Current Liabilities stood at $335000.0 in 2021, then declined by 4.18% to $321000.0 in 2022, then fell by 8.41% to $294000.0 in 2023, then slipped by 4.76% to $280000.0 in 2024, then tumbled by 67.14% to $92000.0 in 2025.
- Business Quant data shows CELU's Other Non-Current Liabilities at $92000.0 in Q4 2025, $269000.0 in Q3 2025, and $8.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 92,000.00 |
| Sep 30, 2025 | 269,000.00 |
| Jun 30, 2025 | 8.78 Mn |
| Mar 31, 2025 | 8.07 Mn |
| Dec 31, 2024 | 280,000.00 |
| Sep 30, 2024 | 4.40 Mn |
| Jun 30, 2024 | 8.09 Mn |
| Mar 31, 2024 | 15.09 Mn |
| Dec 31, 2023 | 294,000.00 |
| Sep 30, 2023 | 296,000.00 |
| Jun 30, 2023 | 6.28 Mn |
| Mar 31, 2023 | 318,000.00 |
| Dec 31, 2022 | 321,000.00 |
| Sep 30, 2022 | 14.09 Mn |
| Jun 30, 2022 | 939,000.00 |
| Mar 31, 2022 | 1.90 Mn |
| Dec 31, 2021 | 335,000.00 |
| Sep 30, 2021 | 37.19 Mn |
| Jun 30, 2021 | 29.35 Mn |
| Mar 31, 2021 | 23.79 Mn |